Non-small cell lung cancer, ROS1-positive

From - A Hematology Oncology Wiki
Jump to: navigation, search

Section editor
Travis Osterman, DO, MS
Nashville, TN

Twitter: TravisOsterman

Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.

1 regimens on this page
1 variants on this page

Advanced or metastatic disease, ROS1 inhibitor-naive

Crizotinib monotherapy

back to top


Study Evidence Efficacy
Shaw et al. 2014 Phase I, >20 pts ORR: 72% (95% CI, 58-84)


28-day cycles


  1. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71. Epub 2014 Sep 27. link to original article link to PMC article contains verified protocol PubMed